Stem Cells International / 2018 / Article / Tab 3

Review Article

Intraparenchymal Neural Stem/Progenitor Cell Transplantation for Ischemic Stroke Animals: A Meta-Analysis and Systematic Review

Table 3

Subgroup meta-analysis and metaregression of variants correlated with infarct volume reduction.

Clinical variantsEffect size (95% CI), valuedfUnivariate analysis (, )

Administration time poststroke26.92%, 0.008
 ≤24 h1.57 (1.03–2.21)58.3%, 0.00810
 1–7 d1.64 (1.11–2.16)0.0%, 0.4965
 ≥7 d0.44 (−0.17–1.04)81.8%, ≤0.00110
Cell dosage1.27%, 0.261
 ≤1 × 106 cells/kg1.45 (0.99–1.91)57.4%, 0.0129
 1–5 × 106 cells/kg0.82 (0.06–1.59)83.1%, ≤0.00110
 >5 × 106 cells/kg0.99 (0.25–1.73)61.5%, 0.0166
Animal model0.79%, 0.280
 Transient1.24 (0.82–1.67)68.9%, ≤0.00119
 Permanent0.78 (−0.07–1.64)82.7%, ≤0.0017
Graft sites
 Global0.24 (−0.59–1.08)40.1%, 0.19612.06%, 0.201
 Focal1.19 (0.78–1.60)75.2%, ≤0.00125
Cell donor species20.00%, 0.025
 Mouse1.46 (0.84–2.08)54.7%, 0.0317
 Rat1.73 (1.15–2.31)45.7%, 0.0757
 Human0.51 (−0.08–1.10)81.0%, ≤0.00111
Cell recipient species−4.82%, 0.761
 Mouse0.98 (0.40–1.56)31.2%, 0.2015
 Rat1.12 (0.64–1.60)79.8%, ≤0.00120
 Others1.61 (0.35–2.87)0
Immunoreactivity15.24%, 0.044
 No1.52 (1.11–1.93)30.9%, 0.13612
 Yes0.76 (0.21–1.31)82.1%, ≤0.00114
State of donor cells5.14%, 0.115
 PSC-NSPCs0.63 (−0.13–1.38)84.1%, ≤0.0017
 WT-NSPCs1.33 (0.88–1.78)68.2%, ≤0.00119
Immunosuppression drugs−3.64%, 0.657
 No1.17 (0.22–2.12)78.6%, ≤0.0016
 Yes0.95 (0.32–1.58)83.2%, ≤0.00111
 Unknown1.28 (0.82–1.74)26.9%, 0.2058
Blinding−5.59%, 0.758
 No1.32 (0.17–2.46)85.8%, ≤0.0016
 Yes1.06 (0.67–1.46)69.1%, ≤0.00120
Randomization−3.47%, 0.483
 No1.33 (0.61–2.05)77.1%, ≤0.00110
 Yes0.99 (0.53–1.46)74.6%, ≤0.00116

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.